Geron Corporation (Nasdaq: GERN) and the Biotechnology Research Corporation (BRC) of Hong Kong today announced that Geron has increased its stake in their joint venture entity, TA Therapeutics Limited (TAT), from 50% ownership to 75% ownership.
TAT is a Hong Kong company that conducts research and develops therapeutics based on telomerase activator drugs to restore the functional and regenerative capacity of cells. BRC, a company established by The Hong Kong University of Science and Technology (HKUST), continues to hold the remaining 25% of the shares of TAT.
“TAT has made great progress in its development of telomerase activator compounds for therapeutic applications,” said David J. Earp, J.D., Ph.D., Geron’s senior vice president of business development and a director of TAT. “The company is now expanding its efforts in pre-clinical development and working toward the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration for a small molecule compound for the treatment of HIV/AIDS. This is an opportune time for Geron, the development and commercial partner in the joint venture, to negotiate for a larger interest in the company.”